Verrica Pharmaceuticals (VRCA) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRCA shares.
View VRCA analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month price objectives for Verrica Pharmaceuticals' shares. Their VRCA share price forecasts range from $10.00 to $11.00. On average, they anticipate the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price.
View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts.

Verrica Pharmaceuticals' stock was trading at $2.75 at the beginning of the year. Since then, VRCA shares have increased by 93.5% and is now trading at $5.32.
View the best growth stocks for 2023 here.

Verrica Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,780,000 shares, an increase of 21.1% from the April 30th total of 1,470,000 shares. Based on an average daily volume of 163,600 shares, the days-to-cover ratio is currently 10.9 days. Approximately 7.1% of the company's stock are short sold.
View Verrica Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VRCA earnings forecast.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. The company earned $0.04 million during the quarter. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 50.33% and a negative net margin of 261.70%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS).

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (6.32%), FMR LLC (3.25%), Geode Capital Management LLC (0.43%), BML Capital Management LLC (0.36%), Jane Street Group LLC (0.32%) and Miracle Mile Advisors LLC (0.28%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, John A Stalfort III, Paul B Manning, Paul B Manning, Perceptive Advisors Llc and Ted White.
View institutional ownership trends.

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRCA stock can currently be purchased for approximately $5.32.

Verrica Pharmaceuticals (NASDAQ:VRCA) has a market capitalization of $223.21 million and generates $8.64 million in revenue each year. The company earns $-24,490,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The official website for the company is www.verrica.com. The company can be reached via phone at (434) 453-3300 or via email at info@verrica.com.